ERBB2 and breast carcinoma: For example, Herceptin for HER2/neu positive breast cancer [2, 3] and poly(ADP ribose) polymerase (PARP) inhibitors for triple-negative breast cancer with defective DNA-repair [4, 5] are among the recent successes of targeted therapy.